Anhui Huibang Bioengineering Co.
Latest round
- Series C
Last raised
- Dec 2021
Total raised
- Undisclosed
Investors
- 4
About Anhui Huibang Bioengineering Co.
, Ltd. is a biotech company that focuses on the development of in vitro diagnostic reagents. In 2016, the company launched a urine iodine quantitative analysis system. In 2017, the company established a subsidiary Hefei Huibang Biotechnology. In 2019, the company was successfully listed in the Anhui Equity Custody and Trading Center with the listing code: 630215. The company engages in the development of in vitro diagnostic reagents. Its main products include tumor diagnostic reagents, maternal and child health diagnostic reagents, cardiovascular disease detection reagents, and POCT diagnostic reagents. The non-invasive detection system for diabetic kidney disease provides renal biopsy, urine microalbumin and urine haptoglobin and other services.
Who invested in Anhui Huibang Bioengineering Co.
4 investors across 3 rounds
See all investors in Anhui Huibang Bioengineering Co.
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Questions about Anhui Huibang Bioengineering Co.
Who invested in Anhui Huibang Bioengineering Co.?
Anhui Huibang Bioengineering Co. has 4 investors on record across 3 venture rounds. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Anhui Huibang Bioengineering Co. raised?
Anhui Huibang Bioengineering Co. has raised 3 venture rounds. Sign up free to see how much each round raised and the total.
When did Anhui Huibang Bioengineering Co. last raise money?
Anhui Huibang Bioengineering Co.'s most recent round on record is a Series C, in Dec 2021.
What does Anhui Huibang Bioengineering Co. do?
Anhui Huibang Bioengineering Co. is a biotechnology company.
Where is Anhui Huibang Bioengineering Co. headquartered?
Anhui Huibang Bioengineering Co. is headquartered in Hefei, China.
Which VCs invest in companies like Anhui Huibang Bioengineering Co.?
Among active investors with capital left to deploy, Shanghai State-owned Capital Investment Leading Fund, Hui Hua Fund, Yufu Capital and ICBC Capital Management back biotechnology companies at Anhui Huibang Bioengineering Co.'s stage. Their profiles are linked below.
VCs backing biotechnology startups at Series C
Raising like Anhui Huibang Bioengineering Co.? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.